cyc 202 has been researched along with can 508 in 3 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (can 508) | Trials (can 508) | Recent Studies (post-2010) (can 508) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 10 | 0 | 9 |
| Protein | Taxonomy | cyc 202 (IC50) | can 508 (IC50) |
|---|---|---|---|
| Chain A, Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.74 | |
| Cyclin-T1 | Homo sapiens (human) | 0.31 | |
| G1/S-specific cyclin-E2 | Homo sapiens (human) | 3.5 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.35 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.35 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.35 | |
| Cyclin-A2 | Homo sapiens (human) | 0.35 | |
| Ribosomal protein S6 kinase beta-1 | Homo sapiens (human) | 10 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.35 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 1.925 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 1.4 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.35 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.3214 | |
| Cyclin-H | Homo sapiens (human) | 0.35 | |
| Ribosomal protein S6 kinase beta-2 | Homo sapiens (human) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cankar, P; de Azevedo, WF; Dzubák, P; Fischer, PM; Frysová, I; Hajdúch, M; Kontopidis, G; Krystof, V; Látr, A; Orság, M; Paprskárová, M; Rolcík, J; Slouka, J; Srovnal, J; Strnad, M | 1 |
| Baumli, S; Endicott, JA; Fischer, PM; Hole, AJ; Huang, S; Noble, ME; Pepper, C; Shao, H; Shi, S; Wang, S | 1 |
| Abdel-Aziz, HA; Abou-Seri, SM; Bonardi, A; Eldehna, WM; Elgazar, AA; Fahim, SH; Gratteri, P; Kryštof, V; Nocentini, A; Said, MA; Soliman, DH; Supuran, CT | 1 |
3 other study(ies) available for cyc 202 and can 508
| Article | Year |
|---|---|
4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
Topics: Antimetabolites; Azo Compounds; Bromodeoxyuridine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Enzyme Inhibitors; Humans; Immunoblotting; Models, Molecular; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Reverse Transcription; RNA; Structure-Activity Relationship; Substrate Specificity | 2006 |
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Topics: Cyclin-Dependent Kinase 9; Humans; Models, Molecular; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2013 |
Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.
Topics: Antineoplastic Agents; Azo Compounds; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Molecular Docking Simulation; Molecular Structure; Neoplasms; Pyrazoles; Structure-Activity Relationship; Sulfonamides | 2020 |